Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/interindividual-variation-in-the-pharmacokinetics-of-9-NUygHqYpmq
References (26)
-
H. Khiabani, J. Bramness, A. Bjørneboe, J. Mørland (2006)
Relationship Between THC Concentration in Blood and Impairment in Apprehended DriversTraffic Injury Prevention, 7
-
A. Glaz-Sandberg, L. Dietz, H. Nguyen, H. Oberwittler, R. Aderjan, G. Mikus (2007)
Pharmacokinetics of 11‐nor‐9‐Carboxy‐Δ9‐Tetrahydrocannabinol (CTHC) After Intravenous Administration of CTHC in Healthy Human SubjectsClinical Pharmacology & Therapeutics, 82
-
M. Augsburger, N. Donzé, A. Ménétrey, Clarisse Brossard, F. Sporkert, C. Giroud, P. Mangin (2005)
Concentration of drugs in blood of suspected impaired drivers.Forensic science international, 153 1
-
L. Bonhomme‐Faivre, A. Benyamina, M. Reynaud, R. Farinotti, C. Abbara (2008)
Disposition of Delta(9) tetrahydrocannabinol in CF1 mice deficient in mdr1a P‐glycoprotein, 13
-
L. Bornheim, J. Lasker, J. Raucy (1992)
Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol.Drug metabolism and disposition: the biological fate of chemicals, 20 2
-
M. Huestis, Allan Barnes, Michael Smith (2005)
Estimating the Time of Last Cannabis Use from Plasma Δ9-Tetrahydrocannabinol and 11-nor-9-Carboxy-Δ9-Tetrahydrocannabinol ConcentrationsClinical Chemistry, 51
-
L. Bonhomme‐Faivre, A. Benyamina, M. Reynaud, R. Farinotti, C. Abbara (2008)
PRECLINICAL STUDY: Disposition of Δ9 tetrahydrocannabinol in CF1 mice deficient in mdr1a P‐glycoproteinAddiction Biology, 13
-
SV Vormfelde, M. Toliat, M. Schirmer, I. Meineke, P. Nürnberg, J. Brockmöller (2008)
The Polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 Allele *3 Independently Affect Torsemide Pharmacokinetics and PharmacodynamicsClinical Pharmacology & Therapeutics, 83
-
T. Bland, R. Haining, T. Tracy, P. Callery (2005)
CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin.Biochemical pharmacology, 70 7
-
S. Vormfelde, M. Schirmer, M. Toliat, I. Meineke, J. Kirchheiner, P. Nürnberg, J. Brockmöller (2007)
Genetic variation at the CYP2C locus and its association with torsemide biotransformationThe Pharmacogenomics Journal, 7
-
T. DeLozier, Soo-Chin Lee, S. Coulter, B. Goh, J. Goldstein (2005)
Functional Characterization of Novel Allelic Variants of CYP2C9 Recently Discovered in Southeast AsiansJournal of Pharmacology and Experimental Therapeutics, 315
-
O. Drummer, J. Gerostamoulos, H. Batziris, M. Chu, J. Caplehorn, M. Robertson, P. Swann (2004)
The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes.Accident; analysis and prevention, 36 2
-
J. Kirchheiner, J. Brockmöller (2005)
Clinical Consequences of Cytochrome P450 2C9 PolymorphismsClinical Pharmacology & Therapeutics, 77
-
Kazuhito Watanabe, Satoshi Yamaori, Tatsuya Funahashi, Toshiyuki Kimura, I. Yamamoto (2007)
Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.Life sciences, 80 15
-
H. Gjerde, G. Kinn (1991)
Impairment in drivers due to cannabis in combination with other drugs.Forensic science international, 50 1
-
K. Watanabe, S. Narimatsu, T. Matsunaga, I. Yamamoto, H. Yoshimura (1993)
A cytochrome P450 isozyme having aldehyde oxygenase activity plays a major role in metabolizing cannabinoids by mouse hepatic microsomes.Biochemical pharmacology, 46 3
-
J. Kirchheiner, Martina Tsahuridu, Wafaâ Jabrane, I. Roots, J. Brockmöller (2004)
The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations.Personalized medicine, 1 1
-
E. Cone, M. Huestis (1993)
Relating Blood Concentrations of Tetrahydrocannabinol and Metabolites to Pharmacologic Effects and Time of Marijuana UsageTherapeutic Drug Monitoring, 15
-
R. Mechoulam, A. Shani, H. Edery, Y. Grunfeld (1970)
Chemical Basis of Hashish ActivityScience, 169
-
J. Croxford (2003)
Therapeutic Potential of Cannabinoids in CNS DiseaseCNS Drugs, 17
-
S. Agurell, M. Halldin, J. Lindgren, A. Ohlsson, M. Widman, H. Gillespie, L. Hollister (1986)
Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man.Pharmacological reviews, 38 1
-
L. Lemberger, S. Silberstein, J. Axelrod, I. Kopin (1970)
Marihuana: Studies on the Disposition and Metabolism of Delta-9-Tetrahydrocannabinol in ManScience, 170
-
Craig Lee, J. Goldstein, J. Pieper (2002)
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.Pharmacogenetics, 12 3
-
M. Huestis, Allan Barnes, Michael Smith (2005)
Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations.Clinical chemistry, 51 12
-
C. Crespi, V. Miller (1997)
The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.Pharmacogenetics, 7 3
-
J. Blaisdell, Lucia Jorge-Nebert, S. Coulter, S. Ferguson, Su-Jun Lee, B. Chanas, T. Xi, H. Mohrenweiser, B. Ghanayem, J. Goldstein (2004)
Discovery of new potentially defective alleles of human CYP2C9.Pharmacogenetics, 14 8
- Publisher
- Wiley
- Copyright
- © 2009 American Society for Clinical Pharmacology and Therapeutics
- ISSN
- 0009-9236
- eISSN
- 1532-6535
- DOI
- 10.1038/clpt.2008.213
- Publisher site
- See Article on Publisher Site
Abstract
The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered Δ9‐tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9*2 allele status. However, the median area under the curve of THC was threefold higher and that of 11‐nor‐9‐carboxy‐9‐tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes. CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC.
Journal
Clinical Pharmacology & Therapeutics – Wiley
Published: Mar 1, 2009